Keyphrases
Cardiac Amyloidosis
100%
Transthyretin
100%
Transthyretin Amyloidosis
66%
Tafamidis
66%
Thyroxine
50%
Quality of Life
33%
Cardiovascular Hospitalizations
33%
Exercise Tolerance
33%
Hospitalization
16%
Binding Site
16%
Liver
16%
Disease Progression
16%
Pathophysiology
16%
Early Intervention
16%
Amyloid Deposition
16%
Improved Outcomes
16%
Hypertrophic Cardiomyopathy
16%
Heart Failure with Preserved Ejection Fraction (HFpEF)
16%
Small Molecules
16%
Disease Management
16%
Vitamin A
16%
Current Therapies
16%
Small Interfering RNA (siRNA)
16%
Severe Disease
16%
Early Diagnosis
16%
Clinical Practice
16%
Placebo-controlled Randomized Trial
16%
Median Survival
16%
Improved Survival
16%
Antisense Oligonucleotides
16%
Mechanism of Action
16%
Contractility
16%
Cardiovascular Mortality
16%
Aortic Stenosis
16%
Myocardial Layers
16%
Misfolded Proteins
16%
Mechanistic Studies
16%
Symptom Management
16%
Amyloid Protein
16%
Mutant Variants
16%
Progressive Heart Failure
16%
Immunoglobulin Light Chains
16%
Ventricular Relaxation
16%
Insoluble Protein
16%
Small Molecule Therapeutics
16%
Patisiran
16%
Inotersen
16%
Lament
16%
Medicine and Dentistry
Hope
100%
Heart Amyloidosis
100%
Transthyretin
100%
Tafamidis
40%
Amyloid Protein
30%
Thyroxine
30%
Cardiovascular System
20%
Quality of Life
20%
Exercise Tolerance
20%
Tetramer
20%
Placebo
10%
Disease Exacerbation
10%
Randomized Controlled Trial
10%
Hypertrophic Cardiomyopathy
10%
Heart Failure with Preserved Ejection Fraction
10%
Disease Management
10%
Pathophysiology
10%
Congestive Heart Failure
10%
Small Interfering RNA
10%
Early Diagnosis
10%
Muscle Contractility
10%
Binding Site
10%
Aortic Stenosis
10%
Early Intervention
10%
Retinol
10%
Antisense Oligonucleotide
10%
Monomer
10%
Immunoglobulin Light Chain
10%
Patisiran
10%
Inotersen
10%
Diseases
10%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Amyloidosis
100%
Transthyretin
100%
Tafamidis
40%
Amyloid Protein
30%
Thyroxine
30%
Tetramer
20%
Diseases
20%
Placebo
10%
Small Interfering RNA
10%
Randomized Controlled Trial
10%
Pathophysiology
10%
Congestive Heart Failure
10%
Disease Exacerbation
10%
Monomer
10%
Binding Site
10%
Retinol
10%
Antisense Oligonucleotide
10%
Heart Failure with Preserved Ejection Fraction
10%
Hypertrophic Cardiomyopathy
10%
Aortic Stenosis
10%
Immunoglobulin Light Chain
10%
Patisiran
10%
Inotersen
10%
Immunology and Microbiology
Heart Amyloidosis
100%
Wild Type
25%
Exercise Tolerance
25%
Binding Site
12%
Antisense
12%
Muscle Contractility
12%
Immunoglobulin Light Chain
12%
Heart Ejection Fraction
12%
Amyloid
12%